BLFS 241220 25.00C (BLFS241220C25000) Stock Options, News & Quotes

US OptionsDetailed Quotes

BLFS241220C25000

Watchlist

1.85
+0.45+32.14%

15min DelayClose Nov 22 16:00 ET

1.85High1.85Low

Intraday

5D
Daily

News

Maxim Group Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $30
Moomoo NewsNov 21 08:33 ET · Ratings
Biolife Solutions Insider Sold Shares Worth $882,110, According to a Recent SEC Filing
MT NewswiresNov 19 17:40 ET
H.C. Wainwright Maintains BioLife Solutions(BLFS.US) With Buy Rating, Cuts Target Price to $27
Moomoo NewsNov 19 03:36 ET · Ratings
BioLife Solutions Is Maintained at Buy by HC Wainwright & Co.
Dow JonesNov 18 08:06 ET · Ratings
Analyst Expectations For BioLife Solns's Future
BenzingaNov 18 08:00 ET
BioLife Solutions: Strategic Refocus and Strong Q3 Performance Bolster Buy Rating With $27 Price Target
TipRanksNov 18 06:25 ET · Ratings

Comments

EZ_money

Oct 7 10:09

$Clover Health (CLOV.US)$ buy the dip 😁Hedge funds pile into healthcare stocks amid dip, Goldman Sachs says (NYSEARCA:IYH)" data-render="ssr
$BioLife Solutions (BLFS.US)$ $Emergent BioSolutions (EBS.US)$ $Rockwell Medical (RMTI.US)$

Moomoo AI

Mar 12 08:21

BioLife Solutions, despite more cash than debt, is seen as risky due to lack of profitability and negative cash flow. The company's future financial health hinges on its earnings.

Is BioLife Solutions (NASDAQ:BLFS) Using Too Much Debt?

Moomoo AI

Feb 19 04:28

The stock's low price indicates a potential buying opportunity. However, its high beta suggests volatility. The company's optimistic future outlook isn't fully reflected in the current share price.

Is It Time To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?

Moomoo AI

Nov 16, 2023 21:39

BioLife Solutions' worrying forecast of increased losses and reduced revenues could wane investor confidence. The company's long-term business trajectory is vital for creating shareholder value.

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Moomoo AI

Oct 16, 2023 13:37

Lack of insider transactions might be discouraging for the company's share outlook and the stated insider ownership is not really impressive.

Selling BioLife Solutions Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders